Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Mucosal Immunology
|
December 4, 2009
Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels
E J Ciccone, S W Read, P J Mannon, et al.
HIV Clinical Trials
|
August 9, 2013
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection
K J Cortez, M A Proschan, L Barrett, et al.
Psychosomatic Medicine
|
March 10, 1998
Reproducibility of mental stress-induced myocardial ischemia in the Psychophysiological Investigations of Myocardial Ischemia (PIMI)
R M Carney, R P McMahon, K E Freedland, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
July 25, 1998
Rapid early action for coronary treatment: rationale, design, and baseline characteristics. REACT Research Group
D G Simons-Morton, D C Goff, S Osganian, et al.
The American Journal of Clinical Nutrition
|
July 14, 2001
Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial
E Obarzanek, F M Sacks, W M Vollmer, et al.
JAMA
|
June 29, 2000
Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial
R V Luepker, J M Raczynski, S Osganian, et al.
Journal of the American Dietetic Association
|
August 18, 1999
The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group
L P Svetkey, F M Sacks, E Obarzanek, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 2009
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
J B Dinoso, S Y Kim, A M Wiegand, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Mucosal Immunology
|
December 4, 2009
Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels
E J Ciccone, S W Read, P J Mannon, et al.
HIV Clinical Trials
|
August 9, 2013
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection
K J Cortez, M A Proschan, L Barrett, et al.
Psychosomatic Medicine
|
March 10, 1998
Reproducibility of mental stress-induced myocardial ischemia in the Psychophysiological Investigations of Myocardial Ischemia (PIMI)
R M Carney, R P McMahon, K E Freedland, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
July 25, 1998
Rapid early action for coronary treatment: rationale, design, and baseline characteristics. REACT Research Group
D G Simons-Morton, D C Goff, S Osganian, et al.
The American Journal of Clinical Nutrition
|
July 14, 2001
Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial
E Obarzanek, F M Sacks, W M Vollmer, et al.
JAMA
|
June 29, 2000
Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial
R V Luepker, J M Raczynski, S Osganian, et al.
Journal of the American Dietetic Association
|
August 18, 1999
The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group
L P Svetkey, F M Sacks, E Obarzanek, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 2009
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
J B Dinoso, S Y Kim, A M Wiegand, et al.
Page
of 3